文献速递抗栓抗凝管理特殊人群用药

精神分裂症合并房颤患者口服抗凝起始治疗的差异:全国队列研究

Disparities in oral anticoagulation initiation in patients with schizophrenia and atrial fibrillation: A nationwide cohort study.
PubMed 文献 · Br J Clin Pharmacol · 2022-04-08

基于丹麦全国登记数据,匹配分析精神分裂症合并房颤患者口服抗凝起始率。精神分裂症患者(n=673)一年内起始率为33.7%,无精神分裂症者为54.4%,调整后风险差-20.7%(95%CI -24.7至-16.7)。差异随时间缩小但仍显著。

要点

  • 精神分裂症合并房颤患者OAC起始率显著低于匹配对照。
  • 调整后一年内起始风险差为-20.7%(95%CI -24.7至-16.7)。
  • 2000-2011年与2012-2018年分层均显示显著差异。

核心结论

  • 精神分裂症合并房颤患者口服抗凝起始率显著低于匹配的无精神分裂症房颤患者。

研究设计与样本

  • 基于丹麦全国健康登记系统的全国队列研究,纳入精神分裂症合并房颤患者673例,按1:5匹配性别、年龄、卒中风险评分和日历时段至无精神分裂症房颤患者。

主要发现

  • 精神分裂症患者平均年龄69.5岁,女性占50.3%,一年内OAC起始率为33.7%,无精神分裂症者为54.4%。
  • 调整后OAC起始风险差为-20.7(95%CI -24.7至-16.7)。
  • 2000-2011年,精神分裂症患者OAC起始率18.3%,无精神分裂症者42.9%,调整风险差-23.6%(95%CI -28.8至-18.6)。
  • 2012-2018年,精神分裂症患者OAC起始率48.5%,无精神分裂症者65.7%,调整风险差-14.4%(95%CI -20.4至-8.4)。
  • 无论精神分裂症状态,OAC起始率随时间增加。

临床怎么用

  • 临床应关注精神分裂症合并房颤患者口服抗凝起始的差异,避免遗漏卒中预防机会。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Schizophrenia is associated with poor anticoagulation control and clinical prognosis in patients with atrial fibrillation (AF). Little is known about initiation of oral anticoagulation therapy (OAC) in this patient population. METHODS: In the nationwide Danish health registries, we identified all patients with incident AF and schizophrenia with indication for OAC treatment. Patients with schizophrenia (n = 673) were matched 1:5 on sex, age, stroke risk score, and calendar-period to incident AF patients without schizophrenia. We calculated absolute risk and risk difference (RD) of OAC initiation, adjusting for stroke and bleeding risk factors. Analyses were stratified by calendar period (2000-2011 and 2012-2018) to account for changes after the introduction of non-vitamin K OACs (NOAC). RESULTS: Among patients with schizophrenia (mean age 69.5 years, 50.3% females), 33.7% initiated OAC within the first year after AF diagnosis, compared with 54.4% of patients without schizophrenia, corresponding to an adjusted RD of -20.7 (95% confidence interval [CI]: -24.7 to -16.7). OAC initiation increased over time regardless of schizophrenia status. During 2000-2011, 18.3% of patients with schizophrenia and 42.9% without schizophrenia initiated OAC (adjusted RD -23.6%, 95% CI -28.8 to -18.6). During 2012-2018, this was 48.5% and 65.7%, respectively (adjusted RD -14.4%, 95% CI -20.4 to -8.4). CONCLUSION: Initiation of OAC was substantially lower among patients with AF and schizophrenia compared with matched AF peers. These findings accentuate the importance of close attention to disparities in initiation of OAC treatment, and potential missed opportunities for prevention of disabling strokes in AF patients with schizophrenia.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Højen AA, Nielsen PB, Riahi S, et al. Disparities in oral anticoagulation initiation in patients with schizophrenia and atrial fibrillation: A nationwide cohort study. Br J Clin Pharmacol. 2022. PMID: 35355307. doi:10.1111/bcp.15337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。